pyridostigmine bromide has been researched along with 4-aminopyridine in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.11) | 18.7374 |
| 1990's | 5 (18.52) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 9 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Lundh, H; Nilsson, O; Rosén, I | 2 |
| Riggs, JE | 1 |
| Johansson, S; Lundh, H; Nilsson, O; Rosén, I | 1 |
| Adler, M; Macdonald, DA; Parker, GW; Sellin, LC | 1 |
| Massey, JM; Sanders, DB; Tim, RW | 1 |
| Claussen, GC; Kim, DS; Kwon, KH; Mussell, H; Oh, SJ; Tseng, A | 1 |
| Sieb, JP | 1 |
| Newsom-Davis, J | 1 |
| Beeson, D; Burke, G; Cossins, J; Maxwell, S; Newsom-Davis, J; Nicolle, M; Palace, J; Robb, S; Vincent, A | 1 |
| Casanova-Sorní, C; Monte-Boquet, E; Pelufo-Pellicer, A; Poveda-Andrés, JL; Romá-Sánchez, E | 1 |
| Titulaer, MJ; van Gerven, J; Verschuuren, JJ; Willems, LN; Wirtz, PW | 1 |
| Layzer, RB; Sha, SJ | 1 |
| Kishimoto, R; Matsushima, M; Motomura, M; Nakadate, M; Sasaki, H; Shiraishi, H; Tsuji, S; Yabe, I; Yaguchi, H | 1 |
| Deminière, C; Krim, E; Lagueny, A; Shipley, E | 1 |
| de Kam, ML; den Hartigh, J; Schoemaker, RC; Titulaer, MJ; Tjaden, UR; van Dijk, JG; van Gerven, JM; van Hasselt, JG; Verschuuren, JJ; Wirtz, PW | 1 |
| Argov, Z | 1 |
| Al-Diwani, A; Bouzat, C; Buckingham, SD; Hernando, G; Jones, AK; Jones, R; Maynard, TP; Rayes, D; Sattelle, DB | 1 |
| Keogh, M; Maddison, P; Sedehizadeh, S | 1 |
| Maddison, P | 1 |
| Ghazanfari, N; Morsch, M; Phillips, WD; Reddel, SW; Toyka, KV | 1 |
| Beeson, D; Belaya, K; Burke, G; Cossins, J; Finlayson, S; Holton, JL; Norwood, F; Palace, J; Pascual-Pascual, SI; Walls, TJ | 1 |
| Almodovar, JL; Bansagi, B; Hasan, BA; Herrmann, DN; Horvath, R; Littleton, JT; Lochmüller, H; Lofra, RM; Logigian, EL; Sowden, JE; Whittaker, RG; Zuchner, S | 1 |
| Abicht, A; Bestué, M; Camacho, A; Colomer, J; Dusl, M; Evangelista, T; García-Hoyos, M; García-Ribes, A; Jiménez, E; Lochmüller, H; Nascimento, A; Natera-de Benito, D; Ortez, C; Töpf, A; Trujillo-Tiebas, MJ; Vilchez, JJ | 1 |
| Kim, SM; Lee, MK; Sunwoo, IN | 1 |
7 review(s) available for pyridostigmine bromide and 4-aminopyridine
| Article | Year |
|---|---|
Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
Topics: 4-Aminopyridine; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Ambenonium Chloride; Aminopyridines; Calcium; Cholinesterase Inhibitors; Cyclic AMP; Edrophonium; Ephedrine; Germine Acetates; Guanidine; Guanidines; Humans; Myasthenia Gravis; Neostigmine; Neuromuscular Depolarizing Agents; Neuromuscular Junction; Potassium; Pyridostigmine Bromide; Synapses; Synaptic Transmission | 1982 |
[Diagnosis and therapy of congenital myasthenia syndrome].
Topics: 4-Aminopyridine; Adult; Amifampridine; Central Nervous System Stimulants; Child; Cholinesterase Inhibitors; Edrophonium; Enzyme Inhibitors; Ephedrine; Humans; Infant; Infant, Newborn; Male; Myasthenia Gravis; Potassium Channels; Pyridostigmine Bromide; Quinidine; Syndrome; Thymectomy | 1999 |
Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous System; Calcium Channels, P-Type; Calcium Channels, Q-Type; Carcinoma, Small Cell; Cholinesterase Inhibitors; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Neoplasm Proteins; Plasmapheresis; Potassium Channel Blockers; Pyridostigmine Bromide | 2004 |
Available treatment options for the management of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Antineoplastic Agents; Carcinoma, Small Cell; Cholinesterase Inhibitors; Cisplatin; Etoposide; Guanidine; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Immunotherapy; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Parasympathomimetics; Plasmapheresis; Potassium Channel Blockers; Prednisolone; Pyridostigmine Bromide; Randomized Controlled Trials as Topic | 2006 |
Management of myasthenic conditions: nonimmune issues.
Topics: 4-Aminopyridine; Amifampridine; Cholinesterase Inhibitors; Electrodiagnosis; Humans; Myasthenia Gravis; Myasthenic Syndromes, Congenital; Oligodeoxyribonucleotides, Antisense; Potassium Channel Blockers; Pyridostigmine Bromide; Respiratory Insufficiency | 2009 |
Treatment for Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Cholinesterase Inhibitors; Humans; Immunoglobulins, Intravenous; Lambert-Eaton Myasthenic Syndrome; Muscle Strength; Potassium Channel Blockers; Pyridostigmine Bromide; Randomized Controlled Trials as Topic | 2011 |
Treatment in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Antineoplastic Agents; Guanidine; Humans; Immunoglobulins, Intravenous; Lambert-Eaton Myasthenic Syndrome; Placebos; Potassium Channel Blockers; Pyridostigmine Bromide; Randomized Controlled Trials as Topic | 2012 |
2 trial(s) available for pyridostigmine bromide and 4-aminopyridine
| Article | Year |
|---|---|
Distinct phenotypes of congenital acetylcholine receptor deficiency.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Cell Line; Child; Child, Preschool; Cholinesterase Inhibitors; DNA Mutational Analysis; Drug Therapy, Combination; Electric Stimulation; Electromyography; Electrophysiology; Embryo, Mammalian; Ephedrine; Evoked Potentials, Motor; Female; Fluorescent Antibody Technique; Humans; Kidney; Male; Middle Aged; Muscle Proteins; Muscles; Mutation; Myasthenic Syndromes, Congenital; Phenotype; Potassium Channel Blockers; Protein Subunits; Pyridostigmine Bromide; Receptors, Cholinergic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, DNA; Severity of Illness Index; Sympathomimetics; Transfection | 2004 |
Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Humans; Lambert-Eaton Myasthenic Syndrome; Middle Aged; Muscle Strength; Pyridostigmine Bromide; Treatment Outcome | 2009 |
18 other study(ies) available for pyridostigmine bromide and 4-aminopyridine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electromyography; Humans; Male; Middle Aged; Myasthenia Gravis; Neuromuscular Junction; Pyridostigmine Bromide; Synaptic Transmission | 1985 |
Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Autoimmune Diseases; Female; Humans; Middle Aged; Myasthenia Gravis; Pyridostigmine Bromide; Syndrome | 1984 |
Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Amifampridine; Clinical Protocols; Drug Synergism; Drug Therapy, Combination; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Muscles; Neoplasms; Parasympathomimetics; Pyridostigmine Bromide | 1993 |
Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins; Drug Interactions; Male; Muscle, Skeletal; Paralysis; Potassium Channel Blockers; Pyridostigmine Bromide; Rats; Rats, Inbred F344 | 1996 |
Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Autoantibodies; Carcinoma, Small Cell; Child; Cholinesterase Inhibitors; Electrodiagnosis; Female; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Plasmapheresis; Pyridostigmine Bromide; Receptors, Cholinergic | 1998 |
Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Carcinoma, Small Cell; Female; Guanidine; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Parasympathomimetics; Potassium Channel Blockers; Pyridostigmine Bromide; Retrospective Studies; Thyroid Neoplasms | 1998 |
Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome.
Topics: 4-Aminopyridine; Adult; Amifampridine; Apgar Score; Drug Therapy, Combination; Female; Fetal Development; Humans; Infant, Newborn; Male; Myasthenic Syndromes, Congenital; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pyridostigmine Bromide | 2006 |
Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.
Topics: 4-Aminopyridine; Adolescent; Amifampridine; Cholinesterase Inhibitors; Electrodiagnosis; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; Potassium Channel Blockers; Pyridostigmine Bromide; Thymectomy | 2007 |
[Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Lambert-Eaton Myasthenic Syndrome; Lung Neoplasms; Male; Middle Aged; Pyridostigmine Bromide; Treatment Outcome | 2007 |
[Lambert-Eaton Myasthenic Syndrome associated with vocal cord carcinoma].
Topics: 4-Aminopyridine; Amifampridine; Carcinoma, Squamous Cell; Cholinesterase Inhibitors; Electrophysiology; Endoscopy; Exercise; Humans; Lambert-Eaton Myasthenic Syndrome; Laryngeal Neoplasms; Male; Middle Aged; Muscular Diseases; Neural Conduction; Potassium Channel Blockers; Pyridostigmine Bromide; Ulnar Nerve; Vocal Cords; Voice Disorders | 2008 |
A Cys-loop mutation in the Caenorhabditis elegans nicotinic receptor subunit UNC-63 impairs but does not abolish channel function.
Topics: 4-Aminopyridine; Amifampridine; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cholinesterase Inhibitors; Disease Models, Animal; Gene Expression Regulation; Humans; Muscles; Mutation; Myasthenic Syndromes, Congenital; Neuromuscular Junction; Potassium Channel Blockers; Protein Structure, Secondary; Pyridostigmine Bromide; Receptors, Nicotinic; Swimming | 2011 |
Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.
Topics: 4-Aminopyridine; Amifampridine; Animals; Autoantibodies; Cholinesterase Inhibitors; Evoked Potentials; Female; Humans; Immunoglobulin G; Mice; Mice, Inbred C57BL; Muscle Weakness; Muscle, Skeletal; Myasthenia Gravis, Autoimmune, Experimental; Neuromuscular Junction; Pyridostigmine Bromide; Receptor Protein-Tyrosine Kinases; Receptors, Cholinergic | 2013 |
Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1.
Topics: 4-Aminopyridine; Adrenergic beta-2 Receptor Agonists; Adult; Age of Onset; Albuterol; Amifampridine; Biopsy; Cholinesterase Inhibitors; Diagnosis, Differential; DNA Mutational Analysis; Exome; Female; Genetic Testing; Glycosylation; Humans; Male; Middle Aged; Motor Neurons; Muscle, Skeletal; Myasthenic Syndromes, Congenital; N-Acetylglucosaminyltransferases; Neurologic Examination; Neuromuscular Junction; Phenotype; Potassium Channel Blockers; Pyridostigmine Bromide | 2013 |
Electrophysiologic features of SYT2 mutations causing a treatable neuromuscular syndrome.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Child; Electrophysiological Phenomena; Female; Humans; Male; Middle Aged; Mutation; Myasthenic Syndromes, Congenital; Potassium Channel Blockers; Pyridostigmine Bromide; Reflex; Synaptic Transmission; Synaptotagmin II; Young Adult | 2015 |
Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations.
Topics: 4-Aminopyridine; Adolescent; Adult; Amifampridine; Child; Child, Preschool; Cholinesterase Inhibitors; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscle Proteins; Mutation; Myasthenic Syndromes, Congenital; Phenotype; Potassium Channel Blockers; Pyridostigmine Bromide; Young Adult | 2016 |
3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Topics: 4-Aminopyridine; Adult; Aged; Amifampridine; Cholinesterase Inhibitors; Female; Humans; Lambert-Eaton Myasthenic Syndrome; Male; Middle Aged; Myasthenia Gravis; Potassium Channel Blockers; Pyridostigmine Bromide | 2018 |